How to Analyse Pharma Company Results: India, US, Specialty and R&D

A pharmaceutical result should be analysed as a portfolio of businesses, products and regulatory exposures. India branded formulations, US generics, specialty medicines, emerging markets and active ingredients can grow at different rates and carry very different margins and risks. Consolidated revenue growth is therefore only the first line of the analysis. For a company-level map, see how Sun Pharma makes money.

Map revenue before interpreting growth

Start with a geographic and product bridge. Company labels differ, but the usual buckets include:

• India formulations;
• North America or US formulations;
• emerging markets;
• Europe or other developed markets;
• active pharmaceutical ingredients; and
• specialty or innovative products.

For each bucket, separate volume, price, currency, launches and acquisitions where management provides enough evidence. Growth in India branded products can be driven by prescription volumes, price revisions and new launches. US generic revenue can move because of launches, competition, supply disruptions or price erosion.

The distinction matters because the durability is different. A limited-competition product may produce high revenue for a few quarters and then decline when competitors enter. A diversified domestic franchise can be slower but more repeatable.

Use consolidated data as the control total

Altys’s consolidated trailing-year snapshot through June 2026 recorded revenue of approximately ₹59,911 crore for Sun Pharma, ₹28,324 crore for Cipla and ₹33,228 crore for Dr Reddy’s. Reported TTM revenue growth was about 11.4 per cent for Sun Pharma, 1.8 per cent for Cipla and negative 0.9 per cent for Dr Reddy’s.

Those numbers tell us that the aggregate trajectories differed. They do not tell us which geography or product created the difference. The segment and management disclosures must reconcile back to these consolidated totals before the explanation is accepted.

Build a gross-margin and operating-margin bridge

Pharma margins depend heavily on mix. A useful bridge considers:

• branded versus generic products;
• limited-competition launches;
• input and freight costs;
• manufacturing utilisation;
• remediation expenses;
• currency;
• R&D; and
• selling expenditure behind specialty products.

For the trailing year ended June 2026, Altys data showed EBITDA margins of roughly 28.6 per cent for Sun Pharma, 17.7 per cent for Cipla and 15.5 per cent for Dr Reddy’s. Their PAT margins on revenue were about 20.2, 11.9 and 9.7 per cent respectively.

The gap should not be turned into a simplistic quality ranking. Sun Pharma’s specialty mix, each company’s regional exposures, exceptional items and investment intensity have to be considered. The purpose of the comparison is to identify which operating variables explain the gap.

Treat R&D as a portfolio, not one expense line

R&D depresses current profit but may create future products. The analyst needs to understand what the spending is buying.

Record:

1. R&D as a percentage of sales.
2. Generic filings and expected launch windows.
3. Specialty programmes by development stage.
4. Clinical or regulatory milestones.
5. Capitalised versus expensed development costs.
6. Products that were discontinued or impaired.

A rising R&D ratio can be sensible if credible assets are advancing. It can also become a recurring cost with weak commercial output. The history of programmes and launches is more informative than a single percentage.

Maintain a facility-risk map

Regulatory status belongs in the financial model because a plant interruption can affect supplies, launches and costs. Keep a facility-level record of inspections, observations, responses, classifications and products manufactured.

Avoid two common errors. First, do not treat every observation as an import alert. Second, do not treat an apparently resolved issue as irrelevant without checking whether remediation costs or launch delays remain.

The correct question is: which revenue and pipeline assumptions depend on this facility? That links a qualitative regulatory event to a measurable financial exposure.

Examine cash and working capital

Pharma working capital can move with inventory buffers, product launches, channel stocking and receivables across geographies. Compare inventory, receivable and payable days across several quarters, not just one date.

Also examine acquisitions, milestone payments, litigation settlements, tax effects and exceptional income. These can cause PAT to diverge sharply from the operating business. Normalised earnings should remove items that are non-recurring while retaining costs that are genuinely part of operating the portfolio.

The quarterly pharma checklist

1. Revenue bridge by geography and product family.
2. New launches, competition and price erosion.
3. Gross-margin and EBITDA-margin bridge.
4. R&D spend and programme milestones.
5. Facility inspections and remediation.
6. Inventory and receivable movement.
7. Exceptional items and litigation.
8. Guidance and required second-half run rate.
9. Cash generation and capital allocation.
10. Pipeline and facility events to monitor.

Altys helps preserve this structure across financials, filings, concalls, guidance and monitoring. A pharma thesis usually fails through a specific product, facility or market assumption. The research system should make that assumption visible before the headline profit changes.

Data note: Altys consolidated financial snapshot for the trailing 12 months ended 30 June 2026, available by 13 September 2026. Figures are rounded. Operational and regulatory claims should be checked against the relevant company filing and regulator source.